Abstract
There is a trend toward greater use of cosmetic procedures by ethnic minorities. The greatest level of increased interest is among Latino and African American patients, with Latino patients leading all minority groups in the number of cosmetic procedures performed in 2008. African American and Asian American patients closely trail Latino patients, comprising 8% and 7% of all of the cosmetic procedures performed in 2008. The most commonly requested surgical procedures are nose reshaping, breast reduction, and liposuction, whereas botulinum toxin A, facial fillers, and chemical peels are the most commonly requested minimally invasive procedures.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Erbguth FJ. Historical notes on botulinum, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19:S2–6.
Cherington M. Clinical spectrum of botulinum. Muscle Nerve. 1998;21:701–10.
Bengston IA. Studies on organisms concerned as causative factors in botulinum. Hyg Lab Bull. 1924;136:101.
Carruthers JD, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.
Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis: no sweat Botox. Dermatol Surg. 1998;24:817–9.
Curruthers A, Carruthers J. Botulinum toxin type A. J Am Acad Dermatol. 2005;53:284–90.
Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55 Suppl 5:S29–35.
Schwetz BA. First drug for cervical dystonia. JAMA. 2001;285:724.
Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;7:1431–8.
Baumann L, Slezinger A, Halem M, et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of axillary hyperhidrosis. Int J Dermatol. 2005;44:418–24.
Carruthers A, Carruthers J, Kiena K. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996;34:788–95.
Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72:13–24.
Frankel AS. Botox rejuvenation for the periorbital region. Facial Plast Surg. 1999;15:255–62.
Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20:109–20.
Roehm PC, Perry JD, Girkin CA, et al. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuroophthalmol. 1999;19:7–9.
Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549–56.
Wollina U, Konrad H. Managing adverse events associated with botulinum toxin A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6:141–50.
Carruthers A, Carruthers JA. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankivic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Decker Inc; 1994. p. 577–95.
Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22:66–75.
Atamoros FP. Botulinum toxin in the lower third of the face. Clin Dermatol. 2003;21:505–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jones, E., Charles, C.A. (2013). Botulinum Toxin A. In: Alexis, A., Barbosa, V. (eds) Skin of Color. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84929-4_15
Download citation
DOI: https://doi.org/10.1007/978-0-387-84929-4_15
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-84928-7
Online ISBN: 978-0-387-84929-4
eBook Packages: MedicineMedicine (R0)